Shahed Quyyumi, MD
Endocrinology, Diabetes & Metabolism · Staten Island, NYNPI 1487649885
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,523 of the $154,475 with a category attached, or 72.2%. 60 manufacturers reported payments, led by Boehringer Ingelheim at 39.0% of the total. Reporting peaked in 2021 at $43,216 and has fallen 82.3% since, to $7,631 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,613 payments — averaging $95.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$60K
- AstraZeneca$47K
- Lilly USA, LLC$17K
- Novo Nordisk$4K
- Amgen$4K
- Corcept Therapeutics$3K
- plus $19K from 54 others
Across 17 payments — averaging $12,876 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$201K
- Sanofi-aventis U.S. LLC$18K
What the payments were for
- Consulting fees$4,3603%
- Speaking & faculty fees$111,52372%
- Travel & lodging$1,9341%
- Food & beverage$36,56824%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$72,685
- FARXIGA$44,234
- Korlym$2,977
- Minimed 670G System$1,375
- EVENITY$839
- Repatha$617
- AIMOVIG$608
- Omnipod$360
- iLet Bionic Pancreas$303
- Reltone 200 Mg$300
- Reltone 400 Mg$300
- GLYCATE$300
- TZIELD$250
- AFREZZA$237
- DEXCOM G6 TRANSMITTER$225
- VERQUVO$225
- Guardian Connect$220
- DEXCOM G7 GSS (161)$148
- FREESTYLE LIBRE 3$147
- t:slim X2 Insulin Pump with Control-IQ$129
How this compares
$154,475 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,709 | $2,467,776 |
| OzempicSemaglutide | 853 | $1,396,149 |
| TrulicityDulaglutide | 349 | $539,632 |
| Tresiba Flextouch U-200Insulin Degludec | 458 | $527,443 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 432 | $444,023 |
| JardianceEmpagliflozin | 282 | $323,495 |
| FarxigaDapagliflozin Propanediol | 240 | $291,515 |
| AfrezzaInsulin Regular, Human | 69 | $221,379 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 164 | $201,354 |
| SynjardyEmpagliflozin/Metformin Hcl | 151 | $197,947 |
| Xigduo XrDapaglifloz Propaned/Metformin | 122 | $142,414 |
| GlyxambiEmpagliflozin/Linagliptin | 88 | $108,656 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 58 | $87,582 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 93 | $85,091 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $80,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $16,962 | $3,053,2592,084 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus | $4,185 | $1,474,999899 claims |
| Boehringer IngelheimJardiance, Synjardy, Glyxambi, Trijardy Xr, Tradjenta | $60,317 | $891,759725 claims |
| AstraZenecaFarxiga | $47,009 | $291,515240 claims |
| Mannkind CorporationAfrezza | $1,747 | $221,37969 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,889 | $201,354164 claims |
| MerckJanumet Xr, Janumet, Januvia | $820 | $152,801120 claims |
| AmgenProlia | $3,717 | $34,26821 claims |
| Johnson & JohnsonInvokamet | $279 | $31,48320 claims |
| BayerKerendia | $1,272 | $20,09411 claims |
| GSKBreo Ellipta | $48 | $12,51721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Staten Island
- Philip OtterbeckStaten Island$575K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.